Hypopharyngeal Neoplasm Malignant Primary Clinical Trial
Official title:
Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study
TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or >75% partial remission )after inductive chemotherapy, CCRT is suggested as the definitive therapy, for the tumor is sensitive to chemotherapy. If the primary tumor shrinks a little or progresses after inductive chemotherapy, operation is suggested as the definitive therapy to get a longer survival.
| Status | Not yet recruiting |
| Enrollment | 81 |
| Est. completion date | December 30, 2025 |
| Est. primary completion date | October 30, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility | Inclusion Criteria: 1. 18y =age=65y; 2. ECOG:0-1; 3. Histology:squamous cell carcinoma, located in hypopharynx; 4. clinical stage: cT1N1-3M0?cT2-3N0-3M0,organ-preservation-intent regime is made after multidisciplinary treatment(MDT) discussion. Efficacy evaluation will be made according to RECIST 1.1 after inductive chemotherapy, and the following treatment will be chosen according to the results of efficacy evaluation. 5. never received any previous treatment, including radiotherapy, chemotherapy, or immune therapy, et al. 6. at least one measurable lesion (RECIST 1.1 criteria). 7. expected survival =6 months. 8. no contraindications of radiotherapy, chemotherapy and immune therapy. 9. functions of main organs A. WBC=3.0x109 /L,ANC=1.5x109/L B. HB=90g/L C. PLT=100x109 /L D. serum albumin=2.8g/dL E. TBil =1.5xULN,ALT?AST=3.0xULN F. serum creatinine =1.5xULN or creatinine clearance rate>60mL/min(Cockcroft-Gault) G. APTT and INR =1.5xULN 10. contraception 11. voluntary and compliance. Exclusion Criteria: 1. other histology cancers located in hypopharynx. 2. synchronous or metachronous cancers located in other sites. 3. allergy to monoclonal antibody. 4. uncontrollable heart disease or symptoms. 5. uncontrollable infections. 6. fever of unknown origin>38.5? during screening or before administration. 7. active autoimmune disease. 8. history of immunodeficiency disorders, including HIV. 9. active HBV or HCV. 10. history of interstitial lung disease. 11. active tuberculosis. 12. received any drugs listed below: A. received any study drug 4 weeks before first dose of Toripalimab. B. received any anti-cancer drug 4 weeks before first dose of Toripalimab. C. received any glucocorticoids (>10mg prednison per day) 2 weeks before first dose of Toripalimab. D. received any cancer vaccine 4 weeks before first dose of Toripalimab. E. received any operation or trauma 4 weeks before first dose of Toripalimab. F. recruited in other study. 13. uncontrollable hypertension. 14. uncontrollable type 2 diabetes; 15. hemorrhagic tendency. 16. drug or alcoholic abuse. 17. woman during pregnancy or lactation period. |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Cancer Hospital | Beijing | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Sun Yan | Shanghai Junshi Bioscience Co., Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Complete remission rate | Complete remission rate 3 months after treatment | 3 months after treatment | |
| Secondary | ORR | objective response rate | 3 months after treatment | |
| Secondary | DCR | disease control rate | 5 year | |
| Secondary | PFS | progression free survival | 5 year | |
| Secondary | OS | overall survival | 5 year |